Antibe Therapeutics Inc
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSA… Read more
Antibe Therapeutics Inc (ATBPF) - Total Liabilities
Latest total liabilities as of December 2023: $30.43 Million USD
Based on the latest financial reports, Antibe Therapeutics Inc (ATBPF) has total liabilities worth $30.43 Million USD as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Antibe Therapeutics Inc - Total Liabilities Trend (2012–2023)
This chart illustrates how Antibe Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Antibe Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Antibe Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FuelPositive Corp
OTCQB:NHHHF
|
USA | $2.86 Million |
|
AMJ Global Technology
PINK:AMJT
|
USA | $1.19 Million |
|
Arcure SA
PA:ALCUR
|
France | €12.70 Million |
|
Mega Manunggal Property TBK PT
JK:MMLP
|
Indonesia | Rp1.83 Trillion |
|
Apexindo Pratama Duta Tbk
JK:APEX
|
Indonesia | Rp176.34 Million |
|
Vince Holding Corp. Common Stock
NASDAQ:VNCE
|
USA | $192.61 Million |
|
M K Land Holdings Bhd
KLSE:8893
|
Malaysia | RM537.75 Million |
|
GéoMégA Resources Inc
OTCQB:GOMRF
|
USA | $5.30 Million |
Liability Composition Analysis (2012–2023)
This chart breaks down Antibe Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Antibe Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Antibe Therapeutics Inc (2012–2023)
The table below shows the annual total liabilities of Antibe Therapeutics Inc from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-03-31 | $30.39 Million | -5.97% |
| 2022-03-31 | $32.33 Million | +2.69% |
| 2021-03-31 | $31.48 Million | +212.92% |
| 2020-03-31 | $10.06 Million | +36.33% |
| 2019-03-31 | $7.38 Million | +63.39% |
| 2018-03-31 | $4.52 Million | -37.04% |
| 2017-03-31 | $7.17 Million | +42.52% |
| 2016-03-31 | $5.03 Million | +1013.06% |
| 2015-03-31 | $452.13K | -56.23% |
| 2014-03-31 | $1.03 Million | -40.81% |
| 2013-03-31 | $1.74 Million | +339.96% |
| 2012-03-31 | $396.60K | -- |